Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › CCL20 as a predictor of clinical response to IL23-antagonists

CCL20 as a predictor of clinical response to IL23-antagonists

US Patent 11220541 · Granted Jan 11, 2022

Estimated economic value: $616,506,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method and system for predicting wildfire hazard and spread at multiple time sca2024
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitaliz2024
Anti-B7-H1 antibodies for treating tumors2023
Anti-B7-H1 antibodies for treating tumors2023
Genetic polymorphisms associated with cardiovascular disorders and drug response2023
Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rh2023
Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rh2023
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitaliz2022
Prediction of clinical response to IL23-antagonists using IL23 pathway biomarker2021
Prediction of clinical response to IL23-antagonists using IL23 pathway biomarker2021
Prediction of clinical response to IL23-antagonists using IL23 pathway biomarker2021
Prediction of clinical response to IL23-antagonists using IL23 pathway biomarker2021